Bildkälla: Stockfoto

Xbrane Biopharma Q3’21: Eventful Times Ahead - Redeye

Redeye leaves its view on Xbrane following the announcement of its Q3 report. Our view on the figures in the report is undramatic, and the essential near-term event for the company is the filing to FDA, expected to be finalized in the coming months.

Redeye leaves its view on Xbrane following the announcement of its Q3 report. Our view on the figures in the report is undramatic, and the essential near-term event for the company is the filing to FDA, expected to be finalized in the coming months.
Börsvärldens nyhetsbrev
ANNONSER